”After years of research we suddenly realised how to combine our findings. It was a eureka moment.”

Introducing Amferia wound dressing for animal care — binds and kills bacteria without harming the body

How antimicrobial hydrogel can revolutionize clinical treatments

Binds and kills 99.99% of bacteria without harming the body – even resistant bacteria

Binds and kills 99.99% of bacteria without harming the body – even resistant bacteria

How it works:

For decades, we’ve known that antimicrobial peptides are potent killers of bacteria. Peptides carry a positive electrostatic charge, which naturally attracts the negative charge bacteria carry. Once attached, the knife-like structure of peptides puncture bacterial membranes, killing the cells.  

What hasn’t been known—until now—is how to protect vulnerable parts of the peptide from natural enzymes in the human body. In nature, peptides are fragile molecules. Enzymes can destroy them in seconds. To be effective bacteria killers, peptides need protection.  

To be effective bacteria killers, peptides need protection  

Amferia solves that problem with an innovative, patented hydrogel platform that encases peptides in a solid gel, leaving only the knife-like structure free to attract and puncture bacterial cells.

Because peptides kill bacteria in a physical—as opposed to chemical—process, Amferia products kill even bacteria that has become resistant to antibiotic drugs.

Amferia’s hydrogel stabilizes and protects the peptides for up to five days in biological environments, keeping them actively killing bacteria that entire time. Amferia harnesses peptides in a safe, stable, non-toxic and clinically applicable form, allowing them to kill bacteria without harming anything else in the body.

Amferia’s proprietary antimicrobial technology consists of bio-inspired and amphiphilic antibacterial polymers that target, rapidly bind and kill up to 99.99% of bacteria upon contact—including numerous strains of antibiotic resistant bacteria like MRSA and MDR E. Coli

The material is selective and targets only bacteria while being entirely non-toxic to the human and animal body. 

Now, Amferia has developed this platform into its first in-market product—wound dressing for animal care. Ultimately, the goal is to bring this technology into the market as new and effective products to treat patients at risk of acquiring dangerous skin and wound infections. 

Amferia’s approach to killing bacteria

  • 1. Binds and kills bacterial loads in seconds—including antibiotic resistant bacteria
  • 2. Highly potent and targets only bacteria
  • 3. Completely harmless to human and animal cells
  • 4. Does not release any antimicrobials into the wound environment

Using antimicrobial peptides in new ways mimicking the immune system

The science:

Derived from the mammalian immune system, antimicrobial peptides are powerful molecules that can rapidly and selectively kill bacteria—including antibiotic resistant bacteria—and prevent bacterial infections.

Until today, antimicrobial peptides have had poor stability

These peptides have been present in mammals for millions of years and have a unique way of killing bacteria by rapidly disrupting the bacteria’s cell membrane through something called electrostatic and amphiphilic interaction. You can think of peptides as a highly specialised soap-like molecule designed to kill bacterial cells by ripping off their skin. 

Antimicrobial peptides carry a net-positive charge and a molecular structure that includes hydrophobic and hydrophilic characteristics. These two factors allow peptides to attract bacterial cells—which carry a net-negative charge and are also amphiphilic—and bind to them, before puncturing their membrane and killing the cell.

Peptides destroy bacterial cells in a physical process, which means bacteria have a very low probability of evolving resistance the way they have been able to against antibiotics, which work chemically. 

Until today, antimicrobial peptides have had poor stability. In the past, their fragility has made antimicrobial peptides challenging for clinical applications. High doses of antimicrobial peptides were needed, which increased costs and, since at those doses peptides were classified as pharma products, prolonged the time-to-market.

As a result, past efforts to develop market-ready products featuring this valuable antimicrobial technology have faced substantial hurdles.

Amferia has solved this problem by implementing a scientifically robust approach that covalently and permanently bind antimicrobial peptides to the surface of a soft, ordered and amphiphilic hydrogel pad.

These permanent bonds protect the vulnerable portion of the peptide molecule and fix them in place, while leaving their bacteria-killing mechanism free to attract and destroy bacterial cells. They also ensure no peptides leak into the wound. Antimicrobial peptides fixed to an underlying hydrogel pad allowed Amferia to develop a safe, efficient and cost-effective design for an antimicrobial wound dressing.  

Amferia has solved this problem by permanently binding the peptides to an amphiphilic hydrogel

This design provides the needed balance between stability and activity.

The end-product is a singular material that does not leach or release any peptides or substances into the body, but rather acts locally as a contact-killing medical device—which will enable faster clinical translation.

Previous antimicrobial peptide technologies utilize peptides in their pristine form, which renders them inactive in a few minutes. Amferia’s innovation enables the bound peptides to remain stable and active for up to five days. Current testing indicates the product we’re developing for wound care will be shelf-stable for up to eighteen months, and potentially up to two years.

Read about our first product using the technology >

Years of research yield a breakthrough innovation


Amferia’s technology is born out of years of research performed at Chalmers University of Technology. The concept behind Amferia’s antibacterial properties are enabled by a new material known as amphiphilic antimicrobial hydrogel.

An amphiphilic substance is one that displays both hydrophilic and hydrophobic characteristics. Comprised of more than 70% water, the hydrogel is soft and flexible, making it useful for numerous medical applications.

Amferia’s technology is based on a new material known as amphiphilic antimicrobial hydrogels

The surface of amphiphilic hydrogel consists of antimicrobial peptides that are covalently and permanently bound to the hydrogels amphiphilic structure—forming a single material. The material interacts with bacterial cells and, disrupts the bacterial cell wall rapidly, effectively killing the bacteria.

Testing proves that the amphiphilic antimicrobial hydrogel does not release any substances into the wound or the environment. This singular material can be configured into antimicrobial products ranging from wound care dressings to antiseptic sprays to mechanically durable devices such as catheters and implants.  

To date, analysis confirms that Amferia amphiphilic antimicrobial hydrogel has up to 99.99% kill rate against multiple gram-negative and gram-positive bacterial strains, including MRSA, MDR E. Coli and Pseudomonas aeruginosa.

It has also been proven to be non-toxic to the body as per ISO 10993 biocompatibility evaluations, namely acute toxicity, cytotoxicity, skin sensitisation & irritation, implantation and material mediated pyrogenicity. 

Amferia's first product for human wound care and animal wound care has been developed for easy applicability and functionality, as proven in numerous pre-clinical and clinical studies. More products and broader applications are in the pipeline.

Read about possible applications of Amferia's innovation >

Amferia’s technology verified in scientific papers

Scientific evidence:

The antimicrobial efficacy of Amferia’s technology platform and its safety in lab and animal studies have been verified in numerous pre-clinical studies published in peer-reviewed scientific journals.

The studies describe evidence of Amferia’s technology through fluorescence microscopy against multiple strains of bacteria, including resistant bacteria. An animal infection study demonstrates the real-time effectiveness of Amferia hydrogel in eradicating bacteria from a wound. 

In 2022, Amferia’s technology platform was verified in a new form for potential spray-based applications. The base technology was reformulated as small particles that can be sprayed for applications in deep wounds. The results demonstrated excellent reduction of the broad bacterial bio burden including resistant bacteria up to 4 log reduction (or 99.99%) bacterial colonies. This study and others are now published in peer-reviewed scientific journals as listed below. 

Pre-clinical studies in peer-reviewed scientific journals

First human study

Clinical studies:

In a study involving 40 healthy volunteers, Amferia dressing was applied on the intact skin of the subjects’ lower arms. The study was a randomised, double-blinded, placebo-controlled evaluation of the efficacy of Amferia dressing on eradicating bacteria from a clinically relevant surface. 

The human skin is a source of bacteria for certain wound infections, for example in surgery wounds. The reduction of bacteria on skin after three hours of dressing application was examined. An average bacterial reduction by 1,000 times (i.e. 99.9%) was observed after application of Amferia wound dressing. In some cases where bacterial load was high, an almost 99.99% reduction was seen (as below).

The image below shows swab cultures from one sample and demonstrates the antimicrobial efficacy of the Amferia hydrogel wound dressing on human skin. The study and statistical analysis is now completed and published in the Journal of Wound Care.

Our colleague Edvin Blomstrand now holds a PhD in Materials Science from Chalmers

September 26, 2023

Amferia is thrilled to announce that our exceptional Research Engineer, Edvin Blomstrand, has successfully defended his doctoral thesis titled "Amphiphilic Hydrogels Functionalized with Antimicrobial Peptides for Wound Care" at Chalmers tekniska högskola. He now proudly holds the esteemed title of Doctor of Philosophy in Materials Science. During his PhD journey, Edvin's contributions have played a pivotal role in shaping our product development at Amferia. We couldn't be more excited to have him continue this remarkable journey with us. With him on board, we are prepared more than ever to pursue our goals, push the boundaries of innovation, and make a meaningful impact in our field.

Join us in congratulating Dr. Blomstrand on this brilliant achievement, and we look forward to the amazing things to accomplish together in the future!

A warm welcome to Amferia’s new Board Members

September 4, 2023

We are proud to introduce the addition of three remarkable individuals to our Board of Directors. Each new member brings a wealth of diverse experience and knowledge  to our team which will further strengthen Amferia’s position in addressing antibiotic resistance and infection management.  

Alexandra De Wever Treschow has over 15 years of leadership experience within life science management and consulting including 4 years as CEO of diagnostics company Aprovix. Prior to that, Alexandra was managing partner of Stockholm-based inRikta Analys. She is co-founder and currently serves as CEO of NORDx Pharma. She holds a  PhD in Gene Therapy from Karolinska Institutet and an MBA from Quantic School of business and Technology, USA. 

Ulrika Ågren is presently an Investment Manager at Almi Invest focusing on medtech, healthtech and greentech. Ulrika has over 20 years of experience in the med-tech industry with specialisations in  intellectual property, innovation portfolio management, project management and business development. She is a certified board member and previously worked for global medtech companies such as Mölnlycke Health Care where she was Global IP Director and the biotech company Cellartis (now Takara Bio). Before joining Almi Invest Ulrika coached HealthTech startups at Sahlgrenska Science Park.

Jonas Bergman serves as an Investment Director at Chalmers Ventures. He brings with him great insight into the operations of med-tech companiesand how they can create long-term value. Jonas has a Master ofScience in Engineering fromChalmers University of Technology and has been CEO of both listed and unlisted life-sciencecompanies for many years. He has also worked as a management consultant forover 7 years with a particular focus in Biotech.

Amferia’s first human clinical study published

June 26, 2023

We are thrilled to share that our dedicated team at Amferia in collaboration with Chalmers tekniska högskola has published a randomised controlled study in the Journal of Wound Care that demonstrates the outstanding antibacterial performance of our hydrogel wound dressing.  We studied our wound dressing on intact human skin as a model to evaluate the speed and efficacy of the dressing to kill bacteria — and the results were truly remarkable!

By utilizing the Amferia Antimicrobial Hydrogel technology, we eradicated bacteria when placed in contact with skin within a short period of three hours.

By utilizing the Amferia Antimicrobial Hydrogel,   bacteria was eradicated within three hours.

These findings demonstrate the potential of our antibacterial wound dressing to significantly reduce the risk of infection in wounds, offering new possibilities for improved patient outcomes. This study lays the foundation for our future clinical studies in human wounds.

You can now access the article via the link:  https://lnkd.in/eTV7nMZg

Amferia raises SEK 15.4 million to launch innovative antimicrobial wound care dressing

January 27, 2023

The financing was raised from Almi Invest, Chalmers Ventures, and with several angel investors to support launch of Amferia’s first product, a wound care dressing with a patented hydrogel that actively combats infections and kills antibiotic-resistant bacteria.

Amferia's innovative, anti-microbial solution can be used on wide-ranging wounds from simple skin injuries, post-operative wounds to chronic wounds and trauma / burn wounds. The WHO predicts that antibiotic-resistant infections, including those from wounds could become one of the leading causes of both illness and death over the next ten years.

“I am grateful to all our committed investors: Every year, nearly 1 million people die globally because of infections caused by antibiotic-resistant bacteria and at least a quarter of those infections begin with a simple wound on the skin. Amferia's wound care solution is a game-changer and will save lives. The resistance problem is even more challenging within the animal health sector.”, says Agneta Edberg, Chairperson of Amferia.

Amferia's wound care solution is a game-changer and will save lives.

Amferia's patented material, an antimicrobial amphiphilic hydrogel, has been developed through several years of research in collaboration with Chalmers University of Technology and contains molecules inspired by body’s own immune system. The material instantly kills all bacteria (even antibiotic resistant) by binding to and disrupting their cell membranes, all without damaging the body’s own cells or entering the bloodstream. The first product from this technology is a hydrogel wound-care dressing for dry-to-low exuding wounds, while the material is also being investigated for development in several other areas, including sprays for deep wounds, and coatings for implants and a variety of catheters. In September of 2022, Amferia launched its first wound dressings for animal health in Sweden and plan on expanding across Europe during 2023. In parallel, the company is preparing to file for regulatory clearance in the US for human health.

The wound care market currently generates sales for over US $ 2 billion globally with a projected CAGR of 5 %. However, existing alternatives on the market often contain antibiotics that carry the risk of causing resistance or antiseptics that may harm body cells and negative environmental impact.

We already have our first product on the market for animal wound care in Sweden

“The investment enables us to perform three key tasks: scale up and launch our products for animal health in Europe, file for FDA clearance of the application for human health and thirdly initiate more clinical studies in both market segments. This ambition is supported by the fact that we already have our first product on the market for animal wound care in Sweden”, says Anand Kumar Rajasekharan, CEO of Amferia.

Pre-clinical research on new antimicrobial spray and coating technology published

January 26, 2023

Amferia announced today that it has, in collaboration with Chalmers University of Technology, published two important scientific articles in peer-reviewed journals that describe the pre-clinical studies of its platform technology, Amphiphilic Antimicrobial Hydrogel as sprays and coatings for various medical device applications.

Amferia’s platform technology is an amphiphilic antimicrobial hydrogel material that can rapidly bind and kill all types of bacteria, even resistant bacteria, without harming the body. In an effort to enable further applications of this material, Amferia collaborated with Chalmers University of Technology to test and develop the patented technology as sprayable formulation and as coatings fight off bacterial infections in medical devices.

Today, the extensive pre-clinical data from this research has been published in two scientific articles in peer-reviewed journals*. The research was built on the formulation of the Amphiphlic Antimicrobial Hydrogel as small discrete particles, which were then further developed as sprayable form for wound care and as a coating on existing materials like silicone catheters. The results from these studies show powerful antimicrobial effect, safety to human cells while being stable in biological environments such as serum.

The material has been shown to be effective against many different types of bacteria, including those that are resistant to antibiotics

Martin Andersson, Professor at Chalmers University and Co-founder of Amferia − “Our innovation can have a dual impact in the fight against antibiotic resistance. The material has been shown to be effective against many different types of bacteria, including those that are resistant to antibiotics, such as Methicillin-resistant Staphylococcus aureus (MRSA), while also having the potential to prevent infections and thus reduce the need for antibiotics,.”

The research was undertaken based on the strong potential of Amferia’s technology, but also based on a clear need from the human and animal health care system on fighting infections in the context of deep infected wounds as well as for various medical devices such as urinary catheters. Amferia and Chalmers will continue to collaborate on this research and are planning to further study the use of the new formulations in clinical settings, both for human and animal care.

We are seeing the great potential of our technology going beyond wound care into the realm of broader medical devices

Anand Rajasekharan,CEO of Amferia − “This is an important achievement for Amferia as we are seeing the great potential of our technology going beyond wound care into the realm of broader medical devices such as coatings and sprayable systems. Our current product is a wound dressing and we look forward to follow-up the same with these pipeline products that will have a stronger impact for addressing antibiotic resistance.”

*The scientific article on the formation of antimicrobial hydrogel particles as sprays and its in-vitro efficacy, safety and stability is published in Cross-linked lyotropic liquid crystal particles functionalized with antimicrobial peptides, Blomstrand et. al. 2022

*The scientific article on the utilisation of these particles as coatings on silicone materials is published in MultifunctionalSurface Modification of PDMS for Antibacterial Contact Killing andDrug-Delivery of Polar, Nonpolar, and Amphiphilic Drugs, Stepulane et. al. 2022

Agneta Edberg appointed chairperson

July 28, 2022

Agneta has a solid background from the global Life science and Medtech field spanning over 30 years in leading roles such as; Sales &Marketing Director of Pharmacia (Pfizer), Senior VP and CEO of Mylan NordicPharmaceuticals, CEO of NM Pharma and more recently as the COO of Bactigaurd that manufactures a variety of antimicrobial device. Today, she works on theBoard of cutting-edge life-science SME’s guiding the companies for future success. Agneta’s extensive knowledge in the life science industry will be important for Amferia’s scale-up journey in both human and animal wound care.

Anand Kumar Rajasekharan, CEO of Amferia − “It is an honour to work with Agenta, whose impressive knowledge of the field and guidance greatly strengthens Amferia’s position as a competent and cutting-edge SME. We look forward to jointly achieve the upcoming key milestones such as the first product launch for animal health, FDA and CE regulatory processes for human health and establishing a successful sales and marketing foundation for Amferia.”

Agneta Edberg − “Amferia is a company every board person wishes to work for. The technology offers a paradigm shift in wound care with nontoxic properties still killing bacteria, even the resistant ones. In a world where antimicrobial resistance is an increasing challenge to humanity, I am grateful to be a part of reducing that threat”

Amferia at the European Wound Management Association (EWMA) congress 2022 in Paris

May 17, 2022

EWMA is an important congress that brings together clinicians and healthcare  industry for important discussions within wound care for humans and animals. Amferia is eager to present our science, antimicrobial technology and introduce our first wound dressings for animal and human wound  care. We welcome all attendees to our stand located in

room 252A at the  congress venue, Palais  des Congrès de Paris, to know more about Amferia and  clinical evidence for human and animal wound care as well as for an  introduction to our soon-to-be launched wound dressings for animal wound  care. We also invite all  attendees to our scientific talk at the symposium for Veterinary Wound  Healing Association (VWHA) on 24th May at 08:45 hrs room 252A.

US patent granted

May 9, 2022

Amferia AB announced today that it has been granted the foundational patent by the United States Patent and Trademark Office (USPTO)for its innovative antimicrobial material based on an amphiphilic antimicrobial hydrogel. The company is now in its final stages of product development for wound care applications and aims to launch the first product within animal health during 2022.

Top 100 research based innovations of 2021

May 26, 2021

Amferia’s technology recognized as one of the top 100 research based innovations of 2021 by the Royal Swedish Academy of Engineering Sciences.

Amferia & Triolab announce partnership to launch innovative wound care products for animal health

May 6, 2021

The joint partnership with Triolab will enable Amferia to reach the large Swedish veterinary market where wound care and infection prevention is of prime importance, which has been intensified with the growing threat of antibiotic resistant infections. Amferia and Triolab’s partnership will build on extensive data and feedback from Amferia’s ongoing product trials across Europe. The joint efforts will aim to market the products to selective veterinary clinics across Sweden during 2021 and further expansion in 2022.